Enzymatics Unveils Its Most Advanced NGS Data Analysis, Interpretation and Reporting Platform to Date: The Archer™ Analysis Pipeline v3.0

BOULDER, Colo. & BEVERLY, Mass.--()--Enzymatics today launches the Archer™ Analysis Pipeline v3.0, it’s most advanced next-generation sequencing analysis platform to detect and characterize cancer-causing gene fusions and mutations from clinical sample types. The software combines cutting-edge analysis with an intuitive user interface enabling researchers to accurately call known or novel genomic alterations. This tool includes robust quality control systems, clear, detailed analytics, and interactive visualizations using JBrowse, resulting in accurate gene fusion and mutation reporting.

Rich Sjogren, CEO of Baby Genes, Inc. and early adopter of the Archer™ Analysis Pipeline v3.0 commented on his experience with the software. “Baby Genes requires a robust, repeatable workflow from sample accessioning to results reporting. The Archer Analysis Pipeline v3.0 gives us this capability in our post-analytical process. We’ve run multiple samples from one of the most complex DNA panels through the pipeline in record time providing very high concordance across runs and between replicate samples. Our verification samples have been spot on. The Enzymatics team has successfully taken one of the most difficult steps in the entire process and made it virtually turn-key. The Archer Analysis Pipeline v3.0, coupled with the AMP technology, is breakthrough for the entire community."

Learn more about the Archer™ Analysis Pipeline at http://www.enzymatics.com/archer/analysis-pipeline/?=3.0.

The Archer™ NGS Solution

Archer™ NGS utilizes their best-in-class fusion detection technology with a lyophilized workflow and an advanced analysis pipeline to comprehensively detect fusions and mutations from as little as 10ng of nucleic acid. Using Archer’s proprietary Anchored Multiplex PCR (AMP™) technology, researchers can detect and identify fusions without prior knowledge of fusion partners or breakpoints. Archer™ technology is “rapidly, efficiently and definitively defining particular fusion genes critical to compiling uniform cohorts of cancers for translational and outcome studies” states Alex Lazar, Director for Sarcoma and Melanoma Molecular Diagnostics Program at MD Anderson Cancer center.

Archer™ FusionPlex™ assays have been optimized for fusion and mutation detection and characterization, are FFPE compatible, and can run on both Illumina® and Ion Torrent™ next-generation sequencing platforms. Once sequenced, Archer™ FusionPlex™ libraries can be analyzed via the Archer™ Analysis Pipeline, a proprietary informatics analysis package that quickly detects and identifies fusion partners of assay genes as well as selected indels and point mutations.

Note: Archer™ kits and analysis software are for research use only and not for use in diagnostic procedures.

About Enzymatics

Enzymatics is a leading producer of sample preparation reagents, assays, kits and software for life science research and applied science customers worldwide. We are experts in the fields of DNA sequencing and PCR, and our business units include:

  • Reagents
  • Supply Chain Solutions
  • Archer NGS

Our passion for quality, responsiveness and flexibility is catalyzing the genomic healthcare revolution. www.enzymatics.com

Contacts

Enzymatics
Richard Kulesus, 303-357-9001, Ext. 4026
rkulesus@enzymatics.com
or
For Media:
MacDougall Biomedical Communications
Charles Liles, 781-235-3060
cliles@macbiocom.com

Release Summary

Enzymatics launched a new data analysis platform for next-generation sequencing applications. The Archer Analysis Pipeline detects and characterizes cancer-causing gene fusions and mutations.

Contacts

Enzymatics
Richard Kulesus, 303-357-9001, Ext. 4026
rkulesus@enzymatics.com
or
For Media:
MacDougall Biomedical Communications
Charles Liles, 781-235-3060
cliles@macbiocom.com